Anticorps Monoclonal anti-FRS2

FRS2 Monoclonal Antibody for WB, IHC, IF/ICC, ELISA

Hôte / Isotype

Mouse / IgG3

Réactivité testée

Humain

Applications

WB, IHC, IF/ICC, ELISA

Conjugaison

Non conjugué

CloneNo.

4E10H12

N° de cat : 66263-1-Ig

Synonymes

SNT, FRS2alpha, FRS2A, FGFR-signaling adaptor SNT, FGFR substrate 2

---

Galerie de données de validation

• 

  WB analysis of MCF-7 using 66263-1-Ig

  MCF-7 cells were subjected to SDS PAGE followed by western blot with 66263-1-Ig (FRS2 antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HEK-293 using 66263-1-Ig

  HEK-293 cells were subjected to SDS PAGE followed by western blot with 66263-1-Ig (FRS2 antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HeLa using 66263-1-Ig

  HeLa cells were subjected to SDS PAGE followed by western blot with (FRS2 Antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human prostate cancer using 66263-1-Ig

  Immunohistochemical analysis of paraffin-embedded human prostate cancer tissue slide using 66263-1-Ig (FRS2 Antibody) at dilution of 1:400 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human prostate cancer using 66263-1-Ig

  Immunohistochemical analysis of paraffin-embedded human prostate cancer tissue slide using 66263-1-Ig (FRS2 Antibody) at dilution of 1:400 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IF Staining of MCF-7 using 66263-1-Ig

  Immunofluorescent analysis of (-20°C Methanol) fixed MCF-7 cells using FRS2 antibody (66263-1-Ig, Clone: 4E10H12 ) at dilution of 1:400 and CoraLite®488-Conjugated Goat Anti-Mouse IgG(H+L) (SA00013-1).

---

Applications testées

• Résultats positifs en WB: cellules MCF-7, cellules HEK-293, cellules HeLa
• Résultats positifs en IHC: tissu de cancer de la prostate humain; il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.
• Résultats positifs en IF/ICC: cellules MCF-7,

Dilution recommandée

• Western Blot (WB): WB : 1:500-1:2000
• Immunohistochimie (IHC): IHC : 1:50-1:500
• Immunofluorescence (IF)/ICC: IF/ICC : 1:200-1:800

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Informations sur le produit

66263-1-Ig cible FRS2 dans les applications de WB, IHC, IF/ICC, ELISA et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Hôte / Isotype: Mouse / IgG3
• Clonalité: Monoclonal
• Type: Anticorps
• Immunogène: FRS2 Protéine recombinante Ag19299
• Nom complet: fibroblast growth factor receptor substrate 2
• Masse moléculaire calculée: 60 kDa
• Poids moléculaire observé: 68 kDa
• Numéro d’acquisition GenBank: BC021562
• Symbole du gène: FRS2
• Identification du gène (NCBI): 10818
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par protéine A
• Tampon de stockage: PBS with 0.02% sodium azide and 50% glycerol
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

Fibroblast growth factor (FGF) receptor substrate 2 (FRS2) has an alternative name as SNT-1, it is an adapter protein that links activated FGR and NGF receptors to downstream signaling pathways. FGF receptor substrates (FRS2 and FRS3) are key adaptor proteins that mediate FGF-FGFR signalling in benign as well as malignant tissue. FRS2 is a 508 amino-acid protein,which is phosphorylated on tyrosine residues. The molecular weight of non-phosphorylated FRS2 is 57-68 kDa, but phosphorylated FRS2 is 80-90 kDa. Phosphorylation of FRS2 is associated with activation of a number of MAP kinases. Allele-specific regulation of FGFR2 mRNA expression with a mildly increased breast cancer risk has been reported.

{{ptg:RelatedPrimaryAntibodies}}